| Dr Joshua David Holweger, MD | |
|
1075 N Curtis, Ste 200, Boise, ID 83706-1350 | |
| (208) 367-8333 | |
| (208) 367-2003 |
| Full Name | Dr Joshua David Holweger |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 17 Years |
| Location | 1075 N Curtis, Boise, Idaho |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417102930 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | M-12488 (Idaho) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Alphonsus Medical Center - Nampa | Nampa, ID | Hospital |
| Saint Alphonsus Regional Medical Center | Boise, ID | Hospital |
| Saint Alphonsus Medical Center - Ontario, Inc | Ontario, OR | Hospital |
| St. Alphonsus Medical Center - Baker City | Baker city, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Saint Alphonsus Regional Medical Center Inc | 3476462359 | 509 |
| Saint Alphonsus Regional Medical Center Inc | 3476462359 | 509 |
News Archive
Clinical trials of the new therapy, called Acoustic Coordinated Reset (ACR), have shown that it reduces the loudness and annoyance caused by tinnitus in seven out of 10 patients.
Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, has unveiled its new CELLECTRA®-SP series of hand-held, cordless electroporation devices at the DNA Vaccines 2010 conference being held in New Orleans, LA.
UC Davis health economists have for the first time projected the total costs of caring for all people with autism spectrum disorder (ASD) in the U.S. for the current calendar year and in 10 years if effective interventions and preventive treatments for the condition are not identified and widely available.
Mosquitoes infected with the bacteria Wolbachia are more likely to become infected with West Nile virus and more likely to transmit the virus to humans, according to a team of researchers.
Researchers for Peregrine Pharmaceuticals presented today at the Strategic Research Institute's Clinical-Stage Product Partnering Summit in La Jolla, CA a summary of clinical experience with Tumor Necrosis Therapy (TNT). The TNT technology is being developed in the U.S. and Europe by Peregrine under the trade name Cotara™. Over 200 patients have been treated with TNT world-wide and a TNT product has been approved to treat grade III or IV advanced lung cancer in the People's Republic of China. A Cotara registration study for brain cancer has been approved by the U.S. Food and Drug Administration, and a Phase I colorectal cancer study is on-going at Stanford University Medical Center.
› Verified 6 days ago
| Entity Name | Saint Alphonsus Regional Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649357716 PECOS PAC ID: 3476462359 Enrollment ID: O20040204001036 |
News Archive
Clinical trials of the new therapy, called Acoustic Coordinated Reset (ACR), have shown that it reduces the loudness and annoyance caused by tinnitus in seven out of 10 patients.
Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, has unveiled its new CELLECTRA®-SP series of hand-held, cordless electroporation devices at the DNA Vaccines 2010 conference being held in New Orleans, LA.
UC Davis health economists have for the first time projected the total costs of caring for all people with autism spectrum disorder (ASD) in the U.S. for the current calendar year and in 10 years if effective interventions and preventive treatments for the condition are not identified and widely available.
Mosquitoes infected with the bacteria Wolbachia are more likely to become infected with West Nile virus and more likely to transmit the virus to humans, according to a team of researchers.
Researchers for Peregrine Pharmaceuticals presented today at the Strategic Research Institute's Clinical-Stage Product Partnering Summit in La Jolla, CA a summary of clinical experience with Tumor Necrosis Therapy (TNT). The TNT technology is being developed in the U.S. and Europe by Peregrine under the trade name Cotara™. Over 200 patients have been treated with TNT world-wide and a TNT product has been approved to treat grade III or IV advanced lung cancer in the People's Republic of China. A Cotara registration study for brain cancer has been approved by the U.S. Food and Drug Administration, and a Phase I colorectal cancer study is on-going at Stanford University Medical Center.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Joshua David Holweger, MD 3340 E Goldstone Way, Meridian, ID 83642-1026 Ph: (208) 367-8333 | Dr Joshua David Holweger, MD 1075 N Curtis, Ste 200, Boise, ID 83706-1350 Ph: (208) 367-8333 |
News Archive
Clinical trials of the new therapy, called Acoustic Coordinated Reset (ACR), have shown that it reduces the loudness and annoyance caused by tinnitus in seven out of 10 patients.
Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, has unveiled its new CELLECTRA®-SP series of hand-held, cordless electroporation devices at the DNA Vaccines 2010 conference being held in New Orleans, LA.
UC Davis health economists have for the first time projected the total costs of caring for all people with autism spectrum disorder (ASD) in the U.S. for the current calendar year and in 10 years if effective interventions and preventive treatments for the condition are not identified and widely available.
Mosquitoes infected with the bacteria Wolbachia are more likely to become infected with West Nile virus and more likely to transmit the virus to humans, according to a team of researchers.
Researchers for Peregrine Pharmaceuticals presented today at the Strategic Research Institute's Clinical-Stage Product Partnering Summit in La Jolla, CA a summary of clinical experience with Tumor Necrosis Therapy (TNT). The TNT technology is being developed in the U.S. and Europe by Peregrine under the trade name Cotara™. Over 200 patients have been treated with TNT world-wide and a TNT product has been approved to treat grade III or IV advanced lung cancer in the People's Republic of China. A Cotara registration study for brain cancer has been approved by the U.S. Food and Drug Administration, and a Phase I colorectal cancer study is on-going at Stanford University Medical Center.
› Verified 6 days ago
Dr. Jennifer A Hofstra, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1055 N Curtis Road, Boise, ID 83706 Phone: 757-446-8920 Fax: 757-446-5242 | |
Dr. James Robert Polk, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 1055 N Curtis Rd, Boise, ID 83706 Phone: 208-367-3104 | |
Dr. Michael Frederic Krug, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 500 W. Fort St, # 111, Boise, ID 83702 Phone: 208-422-1000 Fax: 208-422-1319 | |
Derrel V Walker, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 1055 N Curtis Road, Boise, ID 83706 Phone: 208-367-7350 Fax: 208-367-3951 | |
Dr. Janat E. O'donnell, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 500 W. Fort St., # 111, Boise, ID 83702 Phone: 208-422-1325 Fax: 208-422-1319 | |
Carl L Durning, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 6094 W Emerald St, Boise, ID 83704 Phone: 208-367-6575 Fax: 208-367-6597 | |
Dr. Christopher J Goulet, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 6259 W Emerald St, Boise, ID 83704 Phone: 208-489-1900 Fax: 208-375-5286 |